ArticleBMC cancer2026
Preoperative Radiation Therapy and Immediate Breast Reconstruction, a phase 3 randomized controlled trial in the Belgian population (PRADAIIBE): a study protocol.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06739655 (Preoperative Radiation Therapy and Immediate Breast Reconstruction, a Phase 3 Randomized Controlled Trial in the Belgian Population), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Preoperative Radiation Therapy and Immediate Breast Reconstruction, a Phase 3 Randomized Controlled Trial in the Belgian Population
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently there is a wide practice variation in breast reconstruction surgery after mastectomy for breast cancer patients, especially when radiation therapy (RT) is involved. While it is clear from the scientific literature that immediate implant-based reconstruction has an increased complication rate when postmastectomy Radiation therapy (PMRT) is administered, the jury is out on autologous immediate breast reconstructions (IBR). Nevertheless, some clinicians avoid autologous IBR due to aesthetic outcomes being negatively influenced by PMRT. Others only place tissue expanders, or avoid IBR altogether, when PMRT is indicated. This leads to prolonged periods of time where the patient must live without a new breast, inferior aesthetic outcomes, or an increase in complications. This phase 3 clinical trial, building on the PRADA pilot study, will investigate the efficacy and safety of preoperative RT combined with IBR.
methodsIn this open-label, multicentre, phase 3, randomised controlled trial, 180 female participants with a new diagnosis of breast cancer will be enrolled. Participants will be randomised into two groups. The first group (control) will receive the standard of care treatment (SoC) consisting of mastectomy followed by PMRT; in this group the breast reconstruction can be either delayed or immediate. The second group (experimental) consists of preoperative RT followed by mastectomy and IBR. After treatment conclusion, follow-up will take place at 3 months, 1, 2, 5, and 10 years after the last study treatment. The primary outcome is the patient reported outcome measure of satisfaction with breasts (BREAST-Q score) at 1 year of follow-up. Secondary outcomes include cosmetic assessment, quality of life, adverse events, treatment duration, and histopathology response rates, tertiary endpoints include oncological survival outcomes according to DATECAN definitions. The trial sponsor is ZAS vzw, and is funded by ‘Kom op tegen kanker’. DISCUSSION: Preoperative RT has been implemented in multiple other types of cancer and could offer an opportunity to improve aesthetic and quality of life outcomes in breast cancer patients. Based on the PRADA pilot study and similar research, no increase in adverse events or worse oncological outcomes is expected from this change in treatment sequence.
trial registrationClinicalTrials.gov: NCT06739655; First registration: 17-DEC-2024. Local ZAS Augustinus trial-ID: CTO23023GZA; First registration: 22-APR-2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.